| Literature DB >> 19561161 |
Abdiryim Yusup1, Halmurat Upur, Anwar Umar, Benedicte Berke, Dilxat Yimit, Jaya Conser Lapham, Nicholas Moore, Pierrette Cassand.
Abstract
The study tried to assess the chemoprotective effect of abnormal Savda Munziq (ASMq) on 1,2-dimethylhydrazine (DMH)-induced rat colon carcinogenesis. Male F344 rats were randomized into eight groups: Group 1 was served as control, no DMH injection was given and treated daily with normal saline. Rats in Groups 2-8 were given a single intraperitoneal injection of DMH (20 mg/kg body weight) at the beginning of the study. Group 2 was served as negative control, administered with normal saline until the end of the experiment after the single DMH injection. Groups 3-5 were served as pretreatment group, administered with ASMq ethanol extract at 400, 800 and 1600 mg/kg body weight, respectively, until the 45th day, continued by normal saline administration for another 45 days. Groups 6-8 were served as the treatment group, administered with normal saline for the first 45 days from the day of DMH injection, ASMq ethanol extract at three different doses to be administered until the end of the second 45th day. All rats were sacrificed at 91st day and the colons were analyzed for aberrant crypt foci (ACF) formation and crypt multiplicity. Results showed that ASMq ethanol extract reduced the number of ACF, AC and crypt multiplicity significantly (P < .05). It suggested that ASMq ethanol extract had chemoprotective effects on DMH-induced colon carcinogenesis, by suppressing the development of preneoplastic lesions, and probably exerted protection against the initiation and promotion steps of colon carcinogenesis.Entities:
Year: 2011 PMID: 19561161 PMCID: PMC3136791 DOI: 10.1093/ecam/nep059
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Herbal composition of ASMq [4, 5].
| Plant name | Family name | Uighur name | Used parts |
|---|---|---|---|
|
|
| Pirsiyavxan | Whole plant |
|
|
| Yantak xikiri | Branch secretion |
|
|
| Gavzivan | Aerial parts |
|
|
| Serpistan | Fruit |
|
|
| Xahtere | Whole plant |
|
|
| Arpabidiyan | Fruit |
|
|
| Qüqük buya yiltizi | Radix or rhizoma |
|
|
| Üstihuddus | Aerial parts |
|
|
| Badrenjibuya hindi | Whole plant |
|
|
| Qilan | Fruit |
Figure 1Experimental design to evaluate the effect of ASMq ethanol extract on DMH-induced ACF in the rat colon. Open square: normal saline, yellow square: ASMq administration by gavage, DMH treatment: 20 mg/kg body weight intraperitoneal injection, s: sacrifice at 91st day, n: number of animals/group, Group 1: normal control, no treatment, Group 2: negative control, DMH alone, Groups 3–5: pretreatment, ASMq at three different doses (400, 800 and 1600 mg/kg, resp.) and Groups 6–8: treatment, ASMq at three different doses (same as pretreatment group).
Effect of ASMq ethanol extract on ACF formation in DMH-treated rats (mean ± SD).
| Group/treatment | Number of rats | ACF formation in rat colon | |
|---|---|---|---|
| Total AC | Total ACF | ||
| Normal control (NS) | 8 | 0 | 0 |
| Negative control (DMH + NS) | 8 | 129.8 ± 43.7 | 50.3 ± 16.8 |
| Pretreatment (DMH + ASMq 400) | 8 | 105.1 ± 60.9* | 41.9 ± 20.5* |
| Pretreatment (DMH + ASMq 800) | 8 | 91.5 ± 37.4* | 38.8 ± 14.1* |
| Pretreatment (DMH + ASMq 1600) | 8 | 53.4 ± 31.8* | 23.0 ± 14.0* |
| Treatment (DMH + ASMq 400) | 8 | 91.8 ± 33.6* | 35.9 ± 11.8* |
| Treatment (DMH + ASMq 800) | 8 | 81.5 ± 39.5* | 31.0 ± 14.8* |
| Treatment (DMH + ASMq 1600) | 8 | 46.0 ± 25.8* | 22.4 ± 9.3* |
*P < .05 as compared with negative control group.
Effect of ASMq ethanol extract on aberrant crypt multiplicity in DMH-treated rats (mean ± SD).
| Groups/treatment | Number of rats | ACF ≤ 3 | ACF ≥ 4 | AC/ACF |
|---|---|---|---|---|
| Normal control (NS) | 8 | 0 | 0 | — |
| Negative control (DMH + NS) | 8 | 39.3 ± 14.3 | 11.0 ± 3.9 | 2.6 ± 0.2 |
| Pretreatment (DMH + ASMq 400) | 8 | 32.9 ± 14.2 | 9.0 ± 7.3* | 2.4 ± 0.4* |
| Pretreatment (DMH + ASMq 800) | 8 | 32.3 ± 11.2 | 6.5 ± 3.3* | 2.3 ± 0.2* |
| Pretreatment (DMH + ASMq 1600) | 8 | 19.6 ± 12.5* | 3.4 ± 2.9* | 2.3 ± 0.5* |
| Treatment (DMH + ASMq 400) | 8 | 27.8 ± 9.0* | 8.1 ± 3.3* | 2.5 ± 0.2 |
| Treatment (DMH + ASMq 800) | 8 | 24.6 ± 13.3* | 6.4 ± 4.1* | 2.6 ± 0.4 |
| Treatment (DMH + ASMq 1600) | 8 | 19.9 ± 7.3* | 2.5 ± 2.9* | 2.0 ± 0.4* |
*P < .05 as compared with negative control group.